...
首页> 外文期刊>The Biochemical Journal >Cystinuria-specific rBAT(R365W) mutation reveals two translocation pathways in the amino acid transporter rBAT-b(0,+)AT
【24h】

Cystinuria-specific rBAT(R365W) mutation reveals two translocation pathways in the amino acid transporter rBAT-b(0,+)AT

机译:半胱氨酸特异性rBAT(R365W)突变揭示了氨基酸转运蛋白rBAT-b(0,+)AT中的两个易位途径

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Apical reabsorption of dibasic amino acids and cystine in kidney is mediated by the heteromeric amino acid antiporter rBAT/b(0.+)AT (system b(0.+)). Mutations in rBAT cause cystinuria type A, whereas mutations in b(0.+)AT cause cystinuria type B.b(0.+)AT is the catalytic subunit, whereas it is believed that rBAT helps the routing of the rBAT/b(0.+)AT heterodimeric complex to the plasma membrane. In the present study, we have functionally characterized the cystinuria-specific R365W (Arg(365) --> Trp) mutation of human rBAT, which in addition to a trafficking defect, alters functional properties of the b(0.+) transporter. In oocytes, where human rBAT interacts with the endogenous b(0.+)AT subunit to form an active transporter, the rBAT(R365W) mutation caused a defect of arginine efflux without altering arginine influx or apparent affinities for intracellular or extracellular arginine. Transport of lysine or leucine remained unaffected. In HeLa cells, functional expression of rBAT(R365W)/b(0.+)AT was observed only at the permissive temperature of 33 degreesC. Under these conditions, the mutated transporter showed 50% reduction of arginine influx and a similar decreased accumulation of dibasic amino acids. Efflux of arginine through the rBAT(R365W)/b(0.+)AT holotransporter was completely abolished. This supports a two-translocation-pathway model for antiporter b(0.+), in which the efflux pathway in the rBAT(R365W)/b(0.+)AT holotransporter is defective for arginine translocation or dissociation. This is the first direct evidence that mutations in rBAT may modify transport properties of system b(0.+).
机译:肾脏中二元氨基酸和胱氨酸的重吸收是由异聚氨基酸逆转运蛋白rBAT / b(0。+)AT(系统b(0. +))介导的。 rBAT中的突变引起A型胱氨酸尿症,而b(0。+)AT中的突变引起Bb(0。+)AT型胱氨酸尿症是催化亚基,而人们认为rBAT有助于rBAT / b(0。 +)AT异质二聚体复合物质膜。在本研究中,我们已经在功能上表征了人类rBAT的胱氨酸尿症特异性R365W(Arg(365)-> Trp)突变,除了运输缺陷外,它还改变了b(0. +)转运蛋白的功能特性。在卵母细胞中,人rBAT与内源性b(0。+)AT亚基相互作用形成活性转运蛋白,rBAT(R365W)突变引起精氨酸外流缺陷,而不会改变精氨酸流入量或对细胞内或细胞外精氨酸的表观亲和力。赖氨酸或亮氨酸的运输不受影响。在HeLa细胞中,仅在33摄氏度的允许温度下观察到rBAT(R365W)/ b(0。+)AT的功能性表达。在这些条件下,突变的转运蛋白显示精氨酸流入减少了50%,而二价氨基酸的积累减少了。完全消除了精氨酸通过rBAT(R365W)/ b(0。+)AT全转运蛋白的流出。这支持反向转运蛋白b(0. +)的两个转运途径模型,其中rBAT(R365W)/ b(0。+)AT整体转运蛋白的外排途径对于精氨酸转运或解离是有缺陷的。这是第一个直接证据证明rBAT中的突变可能会改变系统b(0. +)的转运性质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号